Medical Journal of Australia

ISSN: 0025-729X
Title: Medical Journal of Australia
Country: Australia
Status: Active
Start Year: 1914
Frequency: Semi-monthly (23/yr.)
Document Type: Journal; Academic/Scholarly
Refereed: Yes
Abstracted/Indexed: Yes
Media: Print
Alternate Edition: ISSN: 1326-5377
Language: Text in English
Price: AUD 368.50 subscription per year domestic to individuals
Price: AUD 474 subscription per year foreign to individuals
Price: AUD 420 subscription per year domestic to institutions
Price: AUD 530 subscription per year foreign to institutions
Price: AUD 60 subscription per year domestic to students
Price: (effective 2008)

Subject: MEDICAL SCIENCES
Dewey #: 610
LC#: R99
CODEN: MJUAJ
Circulation: 28500 unspecified, Audited by: Circulations Audit Board
Special Features: Includes Advertising, Abstracts, Bibliographies, Illustrations, Book Reviews
Article Index: S-a. index
Editor(s): Martin Van Der Weyden
E-Mail: medjaust@ampco.com.au
URL: http://www.mja.com.au
Description: Covers medical practice and clinical research papers, editorials, original research papers and case reports.

ADDITIONAL TITLE INFORMATION

Alternate Title: Medline Abbreviated title: Med J Aust; Variant title: M J A
Title History: Formed by the merger of (1881-1914): Australasian Medical Gazette (Australia) (0314-5158); (1910-1914): Australian Medical Journal (Australia) (0314-514X); Which was formerly (until 1909): Intercolonial Medical Journal of Australasia (Australia) (1033-3487); Which was formed by the merger of (1895-1896): Intercolonial Quarterly Journal of Medicine and Surgery (Australia) (0816-1941); (1856-1895): The Australian Medical Journal (Australia) (1033-1387)
EDITORIALS
244 From medical school to medical practice: a national tracking system to underpin planning for a sustainable medical workforce in Australasia
John S Humphreys, David Prideaux, Justin J Beilby, Nicholas J Glasgow
246 Child protection and the health professional: mandatory responding is our duty
Peter M Winterton
247 Translational research and rational therapy: structural barriers in Australia
Richard M Fox

RESEARCH
249 An expert-supported monitoring system for patients with chronic obstructive pulmonary disease in general practice: results of a cluster randomised controlled trial
Lisette van den Bemt, Tjard J R Scheiner, Yvo J M Smeele, Leandra JM Boorman-de Winter, Ton van Boxem, Joke Doris, Joke G Grootsen-Stekelenburg, Richard P T M Grof, Chris van Weel

255 Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?
Louise A Keogh, Christine M van Vliet, David M Studdert, Judith A Maskill, Finlay A Macroe, D James St John, Clara L Gaffi, Mary Anne Young, Melissa C Southey, Graham G Giles, Doreen A Rosenthal, John L Hopper, Mark A Jenkins

259 Adequacy of consent documentation in a specialty surgical unit: time for community debate?
Mark T Siddins, Elizabeth M Klinken, Lee R Vocale

SYSTEMATIC REVIEW
263 Is reflexology an effective intervention?
A systematic review of randomised controlled trials
Edzard Ernst

PANDEMIC (H1N1) 2009
267 The community's attitude towards swine flu and pandemic influenza
Holly Seale, Mary-Louise McLaws, Anita E Heywood, Kirsten F Ward, Chris P Lowbridge, Debbie Van, Jan Grafton, C Raina Macintyre

HEALTH CARE REFORM
270 Why health reform?
Steven J Lewis, Stephen R Leedler

VIEWPOINT
273 Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry
Philip B Mitchell

FOR DEBATE
276 A national approach to perinatal mental health in Australia: exercising caution in the roll-out of a public health initiative
Jane S yelland, Georgina A Sutherland, Jan L Wiebe, Stephanie J Brown

RESEARCH ENTERPRISE
280 A case study evaluation of ethics review systems for multicentre clinical trials
Sian C Hicks, Rebecca E James, Nicole Wong, Niall C Tebbutt, Kate Wilson, on behalf of the Australasian Gastro-intestinal Trials Group

DIAGNOSTIC DILEMMAS
284 Acute psychiatric illness in a young woman: an unusual form of encephalitis
Kaitlyn L Parratt, Martin Allan, Simon J G Lewis, Josep Dalmau, Gabor M Halmagyi, Judith M Spies

288 LETTERS (contents overleaf)
From the Editor's Desk

CONFRONTING CONFLICT OF INTEREST

Recently, a French medical organisation initiated legal action against nine doctors for failing to disclose their relationships with drug and other medical industries. At the same time, federal legislators in the United States are moving to enforce mandatory disclosure of industry gifts and payments to doctors on a public website. Indeed, Senator Chuck Grassley of the Senate Committee on Finance is in open conflict with US medical schools over their non-disclosure of drug-firm gifts and payments to faculty members, and is threatening to withhold federal funds. Such developments are testament to an accelerating campaign to confront conflict of interest.

Earlier this year, the US Institute of Medicine (IOM) released a comprehensive report on conflict of interest, covering medical research, education and practice, as well as individual and institutional circumstances. The report advanced wide-ranging recommendations for the handling of conflict of interest in order to "protect the integrity of professional judgment and to preserve public trust". Closer to home, the National Health and Medical Research Council (NHMRC) is currently reviewing its policy on conflict of interest.

It is perhaps surprising that a profession which prides itself on ethical performance should continue to be plagued by lack of transparency in this one area.

But history repeatedly attests to the lure of financial advantage. The IOM has thus recommended that Congress enact legislation requiring companies and their foundations to publicly report payments and gifts made to both individuals and institutions, whether they be physicians or non-physicians prescribing drugs or using medical devices, biomedical researchers, professional societies, continuing medical education providers, or specific patient advocacy groups.

Sadly, our approach to conflict of interest is hopelessly fragmented. The time has come for rhetoric to give way to binding recommendations based on the US model. To make this happen, we need committed leadership and a national organisation with clout.

Martin B Van Der Weyden

LETTERS

288 Australia’s influenza containment plan and the swine flu epidemic in Victoria
Michael G Catton, Julian D Druce, Chris J Birch

288 A pandemic problem with public transport
Benjamin C Cowie

289 First clinical case of a locally acquired carbapenem-resistant VIM-1 metallo-β-lactamase in Pseudomonas aeruginosa in Australia
John Merlino, Harold W Stokes, Elaine Y-L Cheong, Thomas Gottlieb

Meliodosis in south-eastern Queensland
Roger W Guard, Peter J Moren, Win Yi, Maureen J Mackay

Severe Queensland tick typhus complicated by diabetes in south-eastern Queensland
Theo P Birch, Michael Muller

Glycaemic control in patients with type 1 diabetes after provision of public hospital-funded insulin pumps
Ken Y Thong, P Gerry Fegan, Bu B Yeap

Access block: it’s all about available beds
Charles P Denaro

Interventions to circumvent intensive care access block: a retrospective 2-year study across metropolitan Melbourne
Helen E Stark, Chris N Maxwell, Robert W Gibberd

Access block can be managed
Antony Nocera

Should the Pharmaceutical Benefits Advisory Committee extend the range of free nicotine replacement therapies available for Aboriginal and Torres Strait Islander people?
Jan A Robertson, David J MacLaren, Alan R Clough

Poor outcomes among gastrostomy-fed patients in the community
William H Watt, Kate A Needham, Peter L Talbot, Janet P Bell, Glen J Pang

Anxiety and depression among long-term survivors of cancer in Australia: results of a population-based survey
Jeremy W Couper, Anthony W Love, Annabel C Pollard, Sidney Bloch

Malcolm J Wardlaw

Antonina A Mikocka-Walus, Francis T McDermott, Peter A Cameron

SNAPSHOT

275 Three synchronous tumours identified by FDG-PET/CT
Paul M Leong, Michael Lin, Allan R Fowler

CORRECTIONS

296 Retirement intentions of general practitioners aged 45–65 years
(Med J Aust 2009; 191: 75-77)

296 Improving general practice consultations for older people with asthma: a cluster randomised control trial

296 Evolution of a house: Darwin’s link to Pambula

IN THIS ISSUE

287 IN OTHER JOURNALS

MJA Rapid Online Publication: denotes an article fast tracked for online publication.
seasonal influenza of 5%–10%, the likelihood of contracting infection while crammed into under-resourced train networks is significant. In the context of an influenza pandemic, with higher attack rates, the risk is even greater.

Substantial community resources have appropriately been invested in pandemic planning and mitigation strategies. Perhaps, we should devote some of these resources to public transport services to reduce overcrowding. Our national pandemic plan advises that a very simple way of reducing the chances of being infected or passing on infection is to stand or sit back from other people in public or in the workplace. Where possible, you should try to maintain a distance of at least 1 metre, which is about a large step.

Such advice is impossible to follow on peak-period train services, certainly in Melbourne.

Investment in train services to reduce the pread of infections would not only help delay the onset of the next influenza pandemic, but would also reduce seasonal influenza and other respiratory virus transmission. Furthermore, it could avert injuries and illness due to crushing and overheating/dehydration, and could possibly reduce the road toll by taking cars of roads during peak hours. Few season pandemic influenza planning investments could deliver such diverse public health dividends while we ride out the latest influenza pandemic and await the inevitable next one.

Professor C Cowie, Infectious Diseases Physician, and Medical Epidemiologist
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.
jc.cowie@mh.org.au


First clinical case of a locally acquired carbapenem-resistant VIM-1 metallo-β-lactamase in Pseudomonas aeruginosa in Australia
John Merlino, Harold W Stokes, Elaine YL Cheong and Thomas Gottlieb

TO THE EDITOR: Nosocomial infections caused by Pseudomonas aeruginosa often prove difficult to treat because of their resistance to multiple drugs. Carbapenems play a pivotal role in the management of severe multidrug-resistant gram-negative Enterobacteriaceae and P. aeruginosa infections. However, reports in Australia of carbapenem resistance due to production of a variety of carbapenemases, including metallo-β-lactamases (MBLs), have been increasing alarmingly.

We wish to report the first clinical case of a VIM-1-producing MBL in Sydney. To our knowledge, this is the first reported locally acquired case of a P. aeruginosa strain producing acquired VIM-1 MBL in Australia.

The patient was an 81-year-old man with chronic rheumatoid arthritis, managed with prednisone. He had a prostatic kidney infection that was first diagnosed in 1997 and, because of multiple recurrences, had been managed with oral moxifloxacin since 2003. The patient had not travelled outside the Sydney area since before his knee surgery. He was hospitalised in November 2005, when he underwent repair of a colovesical fistula. Carbapenem-resistant P. aeruginosa was isolated repeatedly from both urine and sputum cultures from December 2005 until February 2008, when further testing was performed using newly available molecular real-time polymerase chain reaction (PCR) technology with VIM generic and specific primers and DNA sequencing. This testing detected a VIM-1 gene.

The P. aeruginosa isolates were routinely screened for antibiotic susceptibility. Multi-resistance to numerous antibiotic classes was detected, with high minimum inhibitory concentrations for meropenem, gentamicin, ciprofloxacin, ceftazidime, cepime, piperacillin–tazobactam, and ticarcillin–clavulanic acid. The isolates were susceptible to polymyxin B and aztreonam, and had intermediate resistance to amikacin.

Multiresistant P. aeruginosa is a therapeutic challenge when managing patients with such infections. In the context of facilities such as large burns units or intensive care units, the presence of plasmid-transmissible carbapenem resistance within the gram-negative bacterial population has serious infection control implications. Until novel molecular real-time PCR methods become available, the underlying mechanism of carbapenem resistance in these organisms could not be adequately delineated. The increasing availability of such molecular technology and its routine application in the diagnostic laboratory will support appropriate antibiotic prescribing practices and enhance infection control measures in the hospital setting.

Identification of a plasmid-mediated carbapenem-resistant strain is a concern in our hospital and throughout Australia, as outbreaks of VIM-1 resistance have been reported in Europe and the United States. As demonstrated by our isolates, such strains have a broad spectrum of hydrolytic activity against aminos-, carbamyl- and ureido-penicillins, cephalosporins, cephemycins and carbapenem, but not monobactams. Our isolate was susceptible only to polymyxin and aztreonam.

John Merlino, Senior Scientist
Harold W Stokes, Professor
Elaine YL Cheong, Infectious Diseases Physician and Microbiologist
Thomas Gottlieb, Infectious Diseases Physician and Microbiologist

1 Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW.
2 Institute for the Biotechnology of Infectious Diseases, Faculty of Science, University of Technology Sydney, Sydney, NSW.
jmerlino@med.usyd.edu.au


Published online 24 July 2009.

MJA • Volume 191 Number 5 • 7 September 2009